Effect of soy isoflavone supplementation on blood pressure: a meta-analysis of randomized controlled trials (vol 23, 32, 2024)

被引：0

作者：

Lei, Lifu ^{[1
]}

Hui, Suocheng ^{[2
]}

Chen, Yushi ^{[1
]}

Yan, Hongjia ^{[2
]}

Yang, Jian ^{[3
,4
]}

Tong, Shiwen ^{[1
]}

机构：

[1] Chongqing Med Univ, Dept Clin Nutr, Affiliated Hosp 2, Chongqing 400016, Peoples R China

[2] Peoples Hosp Chongqing Liang Jiang New Area, Dept Clin Nutr, Chongqing 401135, Peoples R China

[3] Chongqing Med Univ, Dept Clin Nutr, Affiliated Hosp 3, Chongqing 410020, Peoples R China

[4] Chongqing Med Univ, Affiliated Hosp 3, Res Ctr Metab & Cardiovasc Dis, Chongqing 410020, Peoples R China

来源：

NUTRITION JOURNAL | 2024年 / 23卷 / 01期

基金：

中国博士后科学基金;

关键词：

Diastolic blood pressure; Dose-response; Hypertension; Soy isoflavone; Systolic blood pressure;

D O I：

10.1186/s12937-024-00941-5

中图分类号：

R15 [营养卫生、食品卫生]; TS201 [基础科学];

学科分类号：

100403 ;

摘要：

BackgroundPrevious experimental studies have suggested that the consumption of soy isoflavones may have a potential impact on lowering blood pressure. Nevertheless, epidemiological studies have presented conflicting outcomes concerning the correlation between soy isoflavone consumption and blood pressure levels. Consequently, a comprehensive meta-analysis of all eligible randomized controlled trials (RCTs) was conducted to explore the influence of soy isoflavones on systolic blood pressure (SBP) and diastolic blood pressure (DBP) in adults.MethodsA thorough search of PubMed, Embase, and the Cochrane Library for relevant literature up to April 30, 2023 was conducted. RCTs involving adults that compared soy isoflavone supplementation with a placebo (the same matrix devoid of soy isoflavone) were included. The combined effect size was presented as the weighted mean difference (WMD) along with 95% confidence interval (CI), employing a fixed-effects model.ResultsOur meta-analysis included a total of 24 studies involving 1945 participants. The results revealed a significant reduction in both SBP and DBP with soy isoflavone supplementation. Subgroup analyses suggested more pronounced reductions in SBP and DBP for interventions lasting >= 6 months, in individuals receiving mixed-type soy isoflavone, and among patients with metabolic syndrome or prehypertension. However, we did not detect significant nonlinear associations between supplementation dosage and intervention duration concerning both SBP and DBP. The overall quality of evidence was deemed moderate.ConclusionsThe current meta-analysis revealed that supplementation with soy isoflavones alone effectively reduces blood pressure. Additional high-quality studies are required to investigate the efficacy of blood pressure reduction through supplementation with an optimal quantity and proportion of soy isoflavone.

引用

页数：7